Overview

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700

Phase:

Phase 1

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Dopamine